By targeting TBRG4 with drugs, it is possible to enhance the ferroptosis of HCC cells through the GPX4/ACSL4 pathway, ultimately improving the prognosis of clinical patients. The gene discussed is TBRG4; the disease is hepatocellular carcinoma.